Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209072 | 0.90 | MTNR1A (0.44) | SLC2A1MTNR1AMTNR1BKCNA3PARP1 | |
| SCHEMBL3154477 | 0.90 | MTNR1A (0.44) | SLC2A1MTNR1AMTNR1BKCNA3PARP1 | |
| SCHEMBL4428657 | 0.90 | MTNR1A (0.44) | SLC2A1MTNR1AMTNR1BKCNA3PARP1 | |
| SCHEMBL5726714 | 0.86 | SLC2A1 (0.61) | SLC2A1KCNH2 | |
| SCHEMBL4491260 | 0.82 | MTNR1A (0.47) | MTNR1AMTNR1BKCNA3PARP1CKS1B | |
| SCHEMBL4468563 | 0.80 | KCNH2 (0.43) | SLC2A1MTNR1AMTNR1BKCNH2 | |
| SCHEMBL5744343 | 0.79 | KCNH2 (0.49) | SLC2A1KCNH2CKS1BSKP1SKP2 | |
| SCHEMBL3144945 | 0.78 | KCNA3 (0.40) | SLC2A1MTNR1AMTNR1BKCNA3KCNH2 | |
| SCHEMBL1267791 | 0.78 | SLC2A1 (0.40) | SLC2A1MTNR1AMTNR1BKCNA3KCNH2 | |
| SCHEMBL3148938 | 0.78 | SLC2A1 (0.41) | SLC2A1MTNR1AMTNR1BKCNA3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498326-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-20060058287-A1 | Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | US | disclosed |
| EP-1583537-A3 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1583537-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004002490-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058287-A1 | Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic | TLR1, TLR2, TLR6 | SLC2A1 3520/4885MTNR1A 1439/4885MTNR1B 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.